### **Supplementary Material**

## Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget's disease of Bone.

Jonathan Philips PhD<sup>1</sup>, Deepak Subedi MB ChB<sup>2</sup>, Steff C Lewis PhD<sup>3</sup>, Catriona Keerie PhD<sup>3</sup>, Owen Cronin PhD<sup>1<sup>+</sup></sup>, Mary Porteous MD<sup>4</sup>, David Moore<sup>4</sup>, Roseanne Cetnarskyj PhD<sup>5</sup>, Lakshminarayan R Ranganath MD, PhD<sup>6</sup>, Peter L Selby MD, <sup>7</sup>, Tolga Turgut MD<sup>7</sup>, Geeta Hampson MD<sup>8</sup>, Rama Chandra MB BS<sup>9</sup>, Shu Ho MD <sup>10</sup>, Jon H Tobias MD, PhD<sup>11</sup>, Steven Young Min PhD <sup>12</sup>, Malachi McKenna MD<sup>13</sup>, Rachel Crowley MD <sup>13</sup>, William D. Fraser MD<sup>14</sup>, Jonathan C.Y. Tang PhD <sup>14,15</sup>, Luigi Gennari MD PhD<sup>16</sup>, Rannuccio Nuti MD <sup>16</sup>, Maria-Luisa Brandi MD PhD<sup>17</sup>, Javier del Pino-Montes MD <sup>18</sup>, Jean-Pierre Devogelaer MD <sup>19</sup>, Anne Durnez MD PhD<sup>19</sup>, Giovanni Carlo Isaia MD<sup>20</sup>, Marco Di Stefano MD<sup>20</sup>, Nuria Guanabens MD<sup>21,</sup> Josep Blanch Rubio MD<sup>22</sup>, Markus J Seibel MD PhD<sup>23</sup>, John P Walsh PhD<sup>24,25</sup>, Sarah Rea PhD <sup>24,25 ‡</sup>, Mark A Kotowicz MB BS <sup>26</sup> Geoffrey C Nicholson PhD <sup>27</sup>, Emma L Duncan PhD <sup>28 §</sup>, Gabor Major MB BS <sup>29,30</sup>, Anne Horne MB, ChB <sup>31</sup>, Nigel Gilchrist MB ChB<sup>32</sup>, Stuart H. Ralston MD<sup>1</sup>

#### **Technical Methods**

#### Routine Biochemistry

Blood samples for routine biochemistry were analysed at the local hospital laboratories of participating centres and measurements were made of serum creatinine, serum total alkaline phosphatase (ALP), calcium, albumin, liver function tests and 25(OH)D according to standard techniques. Measured ALP values were adjusted to the local reference range (RR) to give an adjusted ALP value which was used in statistical analysis. The formula used for calculation was as follows: Adjusted ALP = (measured ALP-ALP lower limit of RR) / (ALP upper limit of RR – ALP lower limit of RR). According to this methodology, a value of 1.0 would equate to an ALP at the upper limit of the reference range, a value of 2.0 to twice the upper limit; a value of 0.5 to the mid-point of the reference range and a value of 0 the lower limit of the reference range.

#### Specialised markers of bone resorption and formation

Measurement of these markers were performed at the University of East Anglia. Blood samples for the markers were obtained between 09.00 and 12.00. Measurements of Type I collagen C-telopeptides (CTX) and Procollagen type I amino-terminal propeptide (PINP) were made on plasma separated from whole blood collected into tubes containing potassium EDTA as an anticoagulant. Bone specific alkaline phosphatase (BAP) was measured on serum separated from whole blood.

Measurements of plasma CTX were made using an Electrochemiluminescence immunoassay (ECLIA) on a Cobas e601 analyser (Roche Diagnostics, Germany). The inter-assay coefficient of variation (CV) for CTX was  $\leq$ 3% between 0.2 and 1.5 µg/L with the sensitivity of 0.01 µg/L. The reference ranges in women were; 0.16-0.57 µg/L (age<50); 0.25-1.02 µg/L (age>50) and in men were; 0.19-0.58 µg/L (age 30-50), 0.19-0.70 µg/L (age 50-70), and 0.19-0.85 µg/L (age >70). Measurements of PINP were also made by ECLIA on a Cobas e601 analyser. The P1NP inter-assay CV was  $\leq$ 3% between 20-600 µg/L with the sensitivity of 8 µg/L. The reference range in premenopausal women was 15-58.6 µg/L; in post-menopausal women 20.3-76.3 µg/L, and in men 20-76 µg/L). Serum bone-specific alkaline phosphatase (BAP) was measured using the MicroVue enzyme immunoassay (Quidel, Athens, OH, USA). Inter-assay CV for BAP was  $\leq$ 2.4% up to the concentration of 140 U/L with the lower limit of sensitivity at 0.7 U/L. The reference ranges in pre-menopausal women were 11.6-29.6 U/L, in post-menopausal women 14.2-42.7 U/L and in men 15-41.2 U/L).

#### Supplementary Table 1. Country and site-specific ethical approvals

Country	Site	REC reference	REC Name
Australia	Brisbane	HREC/12/QRBW/199	Royal Brisbane & Women's Hospital Human Research Ethics Committee (HREC)
Australia	Geelong	46631	Barwon Health Human Research Ethics Committee (HREC)
Australia	Newcastle Sydney	2019/ETH07835	Concord Repatriation General Hospital (CRGH) Human Research Ethics Committee (HREC)
Australia	Perth	RGS000001553	Sir Charles Gairdner Group (SCGG) Human Research Ethics Committee (HREC)
Australia	Toowoomba	#12/04	St Vincent's Health and Aged Care Human Research Ethics Committee (HREC)
Belgium:	Brussel	2010/050CT/308	Comité d'Éthique Hospitalo- Facultaire
Ireland:	Dublin	ZiPP Trial	SVHG Ethics and Medical Research Committee
Italy	Siena	2008-005667-34	Comitato Etico Locale per la Sperimentazione Clinica Dei Medicinal dell'Azienda Ospideliera Universitaria seenese di Siena
Italy	Turin	2008-005667-34	Comitato etico dell Azienda Ospedaliera Universitaria S Giovanni Battista Di Torino
Italy	Florence	2008-005667-34	Comitato etico dell Azienda Ospedaliera Universitaria Careggi
New Zealand:	Auckland	13/STH/32/AM13	Southern Health and Disability Ethics Committee
New Zealand	Christchurch	13/STH/32/AM13	Southern Health and Disability Ethics Committee
Spain:	Salamanca	09/813	CEIM Área de Salud de Salamanca
Spain:	Barcelona	09/813	CEIM Área de Salud de Salamanca

#### Supplementary Table 2. Participating centres

Liverpool	Manchester
Principal Investigator	Principal Investigator
	Email: peter.selby@mft.nhs.uk
Department of Clinical Biochemistry and	
Metabolic Medicine,	
The University of Liverpool	
Liverpool	
L69 3GA	
United Kingdom	
Tel: 0151 706 4197	
Email:	
London Guys	Oswestry
Principal Investigator	Principal Investigator
Dr Geeta Hampson	Dr Shu Ho
Department of Rheumatology,	The Robert Jones and Agnes Hunt Orthopaedic and
St. Thomas' Hospital,	District Hospital,
London,	Oswestry,
SE1 7EH	SY10 7AG
United Kingdom	United Kingdom
Tel: 0207 188 1284	Tel: 01691 404354
Email: geeta.hampson@kcl.ac.uk	Email: <u>Shu.Ho@nhs.net</u>
London Kings College	Portsmouth
Principal Investigator	Principal Investigator
Dr Rama Chandra	Dr Steven Young Min
Clinical Biochemistry,	Department of Rheumatology,
King's College Hospital,	Queen Alexandra Hospital,
London,	Portsmouth,
SE5 9RS	PO6 3LY
United Kingdom	United Kingdom
Tel: 0203 299 3275	Tel: 02392 286199
Email: rama.chandra@nhs.net	Email: <u>Steven.YoungMin@porthosp.nhs.uk</u>
Bristol	Norwich
Principal Investigator	Principal Investigator
Professor Jon Tobias	Professor William Fraser
Musculoskeletal Research Unit,	Norwich Medical School,
University of Bristol,	Faculty of Medicine and Health Sciences,
BS10 5NB	University of East Anglia,
United Kingdom	Norwich,
Tel: 02392 286199	NR4 7TJ,
Email: jon.tobias@bristol.ac.uk	United Kingdom
	Tel: 01159 691 169
	Email: <u>w.fraser@uea.ac.uk</u>

Wrexham	Dublin
Principal Investigator	Principal Investigators
Dr Mark Garton	Dr Malachi Mckenna / Dr Rachel Crowley
Betsi Cadwaladr University Health Board	Endocrinology Department,
/Bwrdd Iechyd Prifysgol Betsi	St. Vincent's University Hospital,
Wrexham Technology Park	Dublin, 4
Wrexham	Republic of Ireland
LL13 7YP	Tel: 01-2214407
United Kingdom	
Tel: 03000 858034	Email: malachimckenna@gmail.com;
Email: Mark.Garton@wales.nhs.uk	rcrowley@svhg.ie
Norwich	Siena
Principal Investigator	Principal Investigators
Dr Jonathan Tang	Dr Luigi Gennari / Professor Rannuccio Nuti
Norwich Medical School,	Department of Medicine,
Faculty of Medicine and Health Sciences,	Surgery and Neurosciences,
University of East Anglia,	University of Sienna,
Norwich, NR4 7TJ,	Sienna,53100
United Kingdom	Italy
Tel: 01159 691 169	Tel: 0577 585 362
Email: <u>Jonathan.Tang@uea.ac.uk</u>	Email: gennari@unisi.it; nutir@unisi.it
Hospital Clinic, Barcelona	Hospital Del Mar, Barcelona
Principal Investigator	Principal Investigator
Dr Nuria Guanabens	Dr Josep Blanch
Department of Rheumatology	Bone Metabolism Unit
Hospital Clinic,	Rheumatology Division,
CIBERehd	University Hospital del Mar
Barcelona 8036	Barcelona 8003
Spain	Spain
Tel: 34932275400	Tel: 34933674126
Email: <u>nguanabens@ub.edu</u>	Email: jblanch@parcdesalutmar.cat
Salamanca	Florence
Principal Investigators	Principal Investigator
Dr Ana Isabel Turrión Nieves	Professor Maria Brandi
Dr Javier del Pino-Montes	Department of Internal Medicine, University Hospital
to attack for plana dia 1 p 1	of Careggi,
Institute for Biomedical Research	0. 00. 088.
Institute for Biomedical Research University Hospital of Salamanca	Florence,
University Hospital of Salamanca	Florence,
University Hospital of Salamanca Salamanca 37007	Florence, 50139
University Hospital of Salamanca Salamanca 37007 Spain	Florence, 50139 Italy

Turin	Brussels
Principal Investigators	Principal Investigators
Professor Giancarlo Isaia / Professor Marco	Dr Anne Durnez / Dr Jean-Pierre Devogelaer
Di Stefano	Service de Rhumatologie
Geriatrics and Metabolic Bone Diseases,	Cliniques Universitaires Saint-Luc,
AOU San Giovanni Battista di Torino Corso,	Brussels, B-1200
Torino, 10126	Belgium
Italy	Tel <u>+32 2 764 5390</u>
Tel: 390116637140	Email: anne.durnez@uclouvain.be;
Email: giancarlo.isaia@unito.it;	jean-pierre.devogelaer@uclouvain.be
mdistefano@cittadellasalute.to.it	
Sydney Concord	Geelong
Principal Investigator	Principal Investigator
Professor Markus Seibel	Prof Mark Kotowicz
Department of Endocrinology and	Department of Endocrinology and Diabetes,
Metabolism,	The University of Melbourne,
Concord Repatriation General Hospital,	Geelong,
Sydney,	3220
NSW 2139	Australia
Australia	Tel: 0061 352 267 764
Tel: 0061 297 676 109	Email: MARKK@barwonhealth.org.au
Email: Markus.seibel@sydney.edu.au	
Perth	Brisbane
Principal Investigator	Principal Investigator
Dr John Walsh	Professor Emma Duncan
Department of Endocrinology and	Endocrinology Department,
Diabetes,	Royal Brisbane and Woman's Hospital, Brisbane,
Sir Charles Gairdner Hospital,	4029
Perth,	Australia
6009	Tel: 0061 7 3636 8111
Australia	Email: emma.duncan@qut.edu.au
Tel: 0061 893 462 466	
Email: John.Walsh@health.wa.gov.au	
Toowoomba	Auckland
Principal Investigator	Principal Investigator
Professor Geoffrey Charles Nicholson	Dr Anne Horne
Rural Clinical School Research Centre, The	Bone & Joint Research Group
University of Queensland, Queensland,	Department of Medicine,
4350	University of Auckland,
Australia	Auckland,
Tel: 00617 4633 9702	New Zealand
Email: geoffn@geelongendo.com.au	Tel: (09) 923 9787
	Email: a.horne@auckland.ac.nz

Newcastle	Christchurch
Principal Investigator	Principal Investigator
Dr Gabor Major	Dr Nigel Gilchrist
Rheumatology,	The CGM Research Trust,
Bone and Joint Institute,	Christchurch,
Royal Newcastle Centre,	8022
New Lambton Heights,	New Zealand.
2305	Tel: 64 333 77820
Australia	Email: <u>nigel.gilchrist@cgm.org.nz</u>
Tel: 02 4922 3500	
Email:	
Gabor.Major@hnehealth.nsw.gov.au	

# Zoledronic Acid<br/>(N=111)Placebo<br/>(N=111)Lesion<br/>(n=9)No Lesion<br/>(n=102)Lesion<br/>(n=12)No Lesion<br/>(n=99)

Supplementary Table 3. Baseline Characteristics of groups with and without bone lesions at baseline

	Lesion (n=9)	No Lesion (n=102)	Lesion (n=12)	No Lesion (n=99)
Female Gender	4 (44.4%)	57 (55.9%)	6 (50.0%)	54 (54.5%)
Type of mutation				
Missense	8 (88.9%)	93 (91.2%)	12 (100.0%)	89 (89.9%)
Truncating	1 (11.1%)	9 (8.8%)	0 (0.0%)	10 (10.1%)
Age band				
30 - 40 years	0 (0.0%)	15 (14.7%)	0 (0.0%)	14 (14.1%)
41 - 50 years	4 (44.4%)	41 (40.2%)	5 (41.7%)	42 (42.4%)
51 - 60 years	3 (33.3%)	36 (35.3%)	5 (41.7%)	31 (31.3%)
61 - 70 years	2 (22.2%)	8 (7.8%)	1 (8.3%)	8 (8.1%)
71+ years	0 (0.0%)	2 (2.0%)	1 (8.3%)	4 (4.0%)
Age (years)				
Mean (SD)	52.7 (9.3)	49.6 (8.8)	53.2 (8.8)	50.2 (9.4)
Median [Q1-Q3]	52.0 [46-55]	49.5 [43-56]	51.0 [49-55]	50.0 [43-56]
Min - Max	41,68	32 , 74	41,75	32 , 75
CTX (ng/mL)				
N (missing)	8 (1)	95 (7)	10 (2)	91 (8)
Mean (SD)	0.40 (0.19)	0.32 (0.17)	0.42 (0.32)	0.34 (0.14)
Median [Q1-Q3]	0.42 [0.27-0.55	0.30 [0.20-0.37	0.37 [0.23-0.44	0.32 [0.24-0.44
Min - Max	0.08 , 0.61	0.09 , 1.24	0.14 , 1.28	0.06 , 0.70
P1NP (ng/mL)				
N (missing)	8 (1)	95 (7)	10 (2)	91 (8)
Mean (SD)	77.8 (34.0)	53.1 (25.7)	104.8 (110.8)	54.6 (19.2)
Median [Q1-Q3]	93.5 [47-106]	48.2 [38-65]	71.8 [56-102]	51.3 [43-63]
Min - Max	22 , 107	21,217	38,412	21 , 127
BALP (U/L)				
N (missing)	8 (1)	95 (7)	10 (2)	90 (9)
Mean (SD)	14.1 (7.6)	10.8 (7.4)	14.0 (16.5)	10.2 (6.5)
Median [Q1-Q3]	15.9 [10-20]	9.1 [6-13]	9.6 [4-12]	9.9 [5-13]
Min - Max	0,22	1,52	3 , 58	1,36
ALP (U/L)				
N (missing)	9 (0)	102 (0)	12 (0)	99 (0)
Mean (SD)	95.0 (34.8)	76.8 (42.1)	131.7 (144.6)	73.9 (21.2)
Median [Q1-Q3]	88.0 [66-113]	72.0 [60-83]	81.0 [65-108]	70.0 [58-86]
Min - Max	58,151	16 , 446	60 , 569	24 , 137

	Zoledronic Acid (N=111)	Placebo (N=111)
Type of Mutation		
Missense	101 (91.0%)	101 (91.0%)
Truncating	10 (9.0%)	10 (9.0%)
Amino Acid Change		
c.1165+1G>A*	5 (4.5%)	3 (2.7%)
p.Thr350GInfsTer28	2 (1.8%)	1 (0.9%)
p.Glu396Ter	1 (0.9%)	3 (2.7%)
p.Gln371Ter	1 (0.9%)	1 (0.9%)
p.Lys378Ter	1 (0.9%)	1 (0.9%)
p.Pro392Leu	64 (57.7%)	77 (69.4%)
p.Met404Val	13 (11.7%)	12 (10.8%)
p.Phe406Val	2 (1.8%)	0 (0.0%)
p.Gly411Ser	7 (6.3%)	2 (1.8%)
p.lle424Ser	2 (1.8%)	0 (0.0%)
p.Gly425Arg	13 (11.7%)	11 (9.9%)

#### Supplementary Table 4. Individual pathogenic variants by study group.

Values are numbers and percentages. \*This is a mutation at a canonical splice donor site at the start of intron 7 which is predicted to disrupt splicing resulting in a truncated protein of 390 amino acids.

.

Allele Frequency				
Amino Acid Change	Study	GnomAD	ACGS Criteria	Pathogenicity
c.1165+1G>A*	0.011	1.36E-05	PVS1_str, PS4, PM1, PP1_str	Pathogenic
p.Thr350fsGlnfsTer28	0.004	4.10E-06	PVS1_str, PS4, PM1, PP1_str	Pathogenic
p.Glu396Ter	0.001	4.10E-06	PVS1_str PS4, PM1, PP1_str	Pathogenic
p.Gln371Ter	0.003	3.60E-06	PVS1_str, PS4, PM1, PP1_str	Pathogenic
p.Lys378Ter	0.003	8.40E-06	PVS1_str, PS4, PM1, PP1_str	Pathogenic
p.Pro392Leu	0.188	0.0014	PP2, PS3_mod, PS4, PM1, PP1_str	Pathogenic
p.Met404Val	0.033	2.91E-05	PP2, PS3_mod, PS4, PM1, PP1_str	Pathogenic
p.Phe406Val	0.003	3.42E-06	PP2, PS3_mod, PS4, PM1, PP1_str	Pathogenic
p.Gly411Ser	0.012	6.13E-05	PP2, PS3_mod, PS4, PM1, PP1_str	Pathogenic
p.lle424Ser	0.003	9.60E-06	PP2, PS3_mod, PS4, PM1, PP1_str	Pathogenic
p.Gly425Arg	0.032	3.15E-05	PP2, PS3_mod, PS4, PM1, PP1_str	Pathogenic

Supplementary Table 5. Pathogenicity of variants assessed by ACGS best practice guidance

The frequency of individual variants in the study population are shown in relation to the frequency in the GnomAD database. The degree of enrichment in the study population over GnomAD ranged from 132-fold for pPro392Leu to 1114-fold for p.Met404Val. Pathogenicity was assessed by the UK Association for Clinical Genomic Science (ACGS) best practice guidelines for variant classification in rare disease [1], which in turn were based on the consensus recommendations of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology [2]

#### Supplementary Table 6. Baseline lesions by country of randomisation

Country	Baseline lesion	No baseline lesion
Australia	3 (8.8%)	31 (91.2%)
υк	11 (8.2%)	123 (91.8%)
Ireland	0 (0.0%)	10 (100.0%)
New Zealand	1 (25.0%)	3 (75.0%)
Spain	4 (22.2%)	14 (77.8%)
Belgium	0 (0.0%)	3 (100.0%)
Italy	2 (10.5%)	17 (89.5%)

Values are numbers (%).

## Supplementary Figure 1. Images of participant who developed a Paget's disease related skeletal event.

A



Panel A. Radionuclide bone scan image showing increased tracer uptake in the cervical spine. Panel B. Radiograph showing expansion of C4 and C5 typical of Paget's disease. The participant was symptom free at baseline but developed symptoms related to Paget's of the cervical spine after about 1 year and required rescue therapy with zoledronic acid.

#### Supplementary Table 7. Quality of Life Questionnaire scores


	Zoledronic Acid (N=111)	Placebo (N=111)	Mean [95% Cl] p-value			
Health	Health Anxiety and Depression Scale (HADS) - Anxiety Score					
Baseline	3.5	3.7	-0.19 [-0.87- 0.49]			
End of Study	3.3	3.7	p-value 0.574			
Health A	Health Anxiety and Depression Scale (HADS) - Depression Score					
Baseline	3.3	3.5	-0.29 [-0.90 - 0.31]			
End of Study	3.1	3.6	p-value 0.340			
	Brief Pain Invent	ory - Interfere	nce Score			
Baseline	1.00	0.82	-0.37 [-0.78 - 0.03]			
End of Study	0.98	1.21	p-value 0.070			
	Brief Pain Inve	ntory - Severit	y Score			
Baseline	1.34	1.24	-0.28 [-0.70- 0.13]			
End of Study	1.38	1.75	p-value 0.175			
SF-36 - Physical Component Score						
Baseline	51.4	51.9	1.60 [-0.24 - 3.43]			
End of Study	51.7	49.7	p-value 0.086			
SF-36 - Mental Component Score						
Baseline	52.5	52.5	0.51 [-1.31- 2.32]			
End of Study	53.3	51.8	p-value 0.584			

Baseline values are means, the end of study values are adjusted least squares means with 95% confidence intervals. HADS anxiety and depression scores can range from 0-21. Higher scores indicate greater levels of anxiety and depression. The BPI score range from 1-10 with higher scores indicating more pain. For SF36 scores lower than 50 indicate lower quality of life and above 50, a higher quality of life.

#### Supplementary Table 8. Adverse events grouped by study group.

	Zoledronic Acid	Placebo	Total
	(n=111)	(n=111)	
Total Adverse Events	583	644	1,227
Blood and lymphatic system disorders	0 (0.0%)	3 (0.5%)	3 (0.2%)
Cardiac disorders	3 (0.5%)	4 (0.6%)	7 (0.6%)
Congenital, familial and genetic disorders	0 (0.0%)	1 (0.2%)	1 (0.1%)
Ear and labyrinth disorders	6 (1.0%)	9 (1.4%)	15 (1.2%)
Endocrine disorders	4 (0.7%)	3 (0.5%)	7 (0.6%)
Eye disorders	5 (0.9%)	6 (0.9%)	7 (0.6%)
Gastrointestinal disorders	30 (5.1%)	47 (7.3%)	77 (6.3%)
General disorders and administration site conditions	10 (1.7%)	21 (3.3%)	31 (2.5%)
Hepatobiliary disorders	0 (0.0%)	6 (0.9%)	6 (0.5%)
Immune system disorders	2 (0.3%)	1 (0.2%)	3 (0.2%)
Infections and infestations	149 (25.6%)	116 (18.0%)	265 (21.6%)
Injury, poisoning and procedural complications	38 (6.5%)	51 (7.9%)	89 (7.3%)
Investigations	45 (7.7%)	57 (8.9%)	102 (8.3%)
Metabolism and nutrition disorders	8 (1.4%)	11 (1.7%)	19 (1.5%)
Musculoskeletal and connective tissue disorders	97 (16.6%)	110 (17.1%)	207 (16.9%)
Neoplasms benign, malignant and unspecified (including cysts and polyps)	12 (2.1%)	7 (1.1%)	19 (1.5%)
Nervous system disorders	36 (6.2%)	31 (4.8%)	67 (5.5%)
Pregnancy, puerperium and perinatal conditions	0 (0.0%)	2 (0.3%)	2 (0.2%)
Product issues	0 (0.0%)	0 (0.0%)	0 (0.0%)
Psychiatric disorders	10 (1.7%)	17 (2.6%)	27 (2.2%)
Renal and urinary disorders	4 (0.7%)	10 (1.6%)	14 (1.1%)
Reproductive system and breast disorders	14 (2.4%)	16 (2.5%)	30 (2.4%)
Respiratory, thoracic and mediastinal disorders	10 (1.7%)	18 (2.8%)	28 (2.3%)
Skin and subcutaneous tissue disorders	9 (1.5%)	17 (2.6%)	26 (2.1%)
Social circumstances	0 (0.0%)	2 (0.3%)	2 (0.2%)
Surgical and medical procedures	86 (14.8%)	68 (10.6%)	154 (12.6%)
Vascular disorders	5 (0.9%)	10 (1.6%)	15 (1.2%)

The adverse events are categorised by the Medical Dictionary for Regulatory Activities – (MedDRA) system organ classes. Values are number and percentages for the events reported.



#### Supplementary Figure 2. Changes in alkaline phosphatase and bone specific alkaline phosphatase

Panel A shows adjusted alkaline phosphatase (ALP). Panel B shows Bone-Specific Alkaline Phosphatase (BAP). Baseline values are means. Subsequent values are adjusted least squares means and 95% confidence intervals. The p-values refer to differences between groups by repeated measures ANOVA taking all observations into account. The unified reference ranges are indicated by horizontal interrupted lines. The baseline values are the means. Subsequent values are adjusted least squares means and 95% confidence intervals. The p-values refer to differences between the groups assessed by repeated measures ANOVA over the whole duration of the study. Unified reference ranges for men and women of all ages are indicated by the interrupted horizontal lines. Measurements of ALP were available at baseline in 103 of the ZA group, 100 at 12 months, 97 at 24 months, 96 at 36 months, 75 at 48 months, 62 at 60 months, and 89 at the end of study. Corresponding values for the placebo group were 101; 97, 91, 93, 74, 50 and 89. Corresponding numbers for BAP in the ZA group were 103, 98, 97, 97, 74, 62, 88 and for placebo group were 100; 97, 91, 93, 75, 51 and 89.

#### References

1. Ellard S BE, Callaway A, Berry A, Forrester N, Turnbulll C, Owens M, Eccles DM, Abbs R, Scott R, Deans ZC, Lester T, Campbell J, Newman WG, Ramsden S, McMullan DJ. ACGS best practice guidelines for Variant Classification in Rare Disease 2020. 2020 [cited 2023; Available from: https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf

2. Richards S, Aziz N, Bale S, *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17:405-424. doi:10.1038/gim.2015.30